Updated:
C3J Therapeutics
C3J Therapeutics is a privately held biotechnology company. The name implies a focus on complement cascade therapeutics, specifically targeting the C3...
C3J Therapeutics
C3J Therapeutics is a privately held biotechnology company. The name implies a focus on complement cascade therapeutics, specifically targeting the C3 protein, a central node in the innate immune system. Dysregulation of the complement pathway is implicated in numerous diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and various autoimmune conditions. The company's research and development efforts are likely aimed at creating inhibitors or modulators of C3 to address these pathologies. No public disclosures detail specific pipeline candidates, funding history, or leadership. Based on available public records, C3J Therapeutics may have ties to academic or biotech hubs in the United States such as Boston or San Diego, though this is unconfirmed. The lack of a corporate website, LinkedIn presence, or press releases suggests the firm is in an early or stealth phase. The broader landscape includes well-capitalized competitors such as Apellis Pharmaceuticals and Alexion Pharmaceuticals, which have advanced complement inhibitors to market. No recent operational events are publicly documented for C3J Therapeutics within the last 24 months. The absence of a public web presence and lack of named principals make it difficult to assess the firm's scale, team composition, or strategic direction. It is possible the entity is a shell or dormant organization, or it may be operating under a different name. The most distinguishing feature of C3J Therapeutics is its apparent exclusivity of focus on the complement C3 target, a narrow therapeutic space that requires significant scientific expertise. However, the lack of verifiable operations or public information strongly limits any institutional assessment. This profile should be treated as highly preliminary until further details emerge.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Stevens Point, Indianapolis, Boston, Melbourne, Radford, Germantown, Roanoke, Oak Brook, Marina del Rey, San Diego
Corporate office
—
Frequently asked questions
What is the primary therapeutic focus of C3J Therapeutics?
The firm's name indicates a focus on the complement C3 protein, a key component of the innate immune system. Targeting C3 is a strategy for diseases involving uncontrolled complement activation, including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and certain autoimmune disorders (public record). This places C3J in a competitive field alongside Apellis Pharmaceuticals and others.
Is C3J Therapeutics a public or private company?
C3J Therapeutics is a private entity. It does not appear on major stock exchanges, and no public filings by the company are available. The firm's opacity suggests it may be in a preclinical or early-stage development phase, possibly funded by founders or a small group of investors.
Has C3J Therapeutics disclosed any pipeline candidates or clinical trials?
No. A review of clinical trial registries and biotech databases reveals no publicly listed drug candidates, trial identifiers, or disclosures by the firm. This absence of data is unusual for therapeutic companies that have reached the clinical stage, supporting the inference that the company may still be in preclinical development or inactive.
Who founded or leads C3J Therapeutics?
Public sources do not list founders, executive team members, or board members for C3J Therapeutics. The firm has no known presence on professional networking platforms or in industry publications. Without this information, it is not possible to attribute leadership or scientific expertise.
Does C3J Therapeutics have a website or public investor relations page?
No operational website for C3J Therapeutics could be identified. The lack of an official web presence is rare for a company in the biotechnology sector, which typically maintains at least a placeholder site. This raises questions about the company's current status.
What is the known funding history of C3J Therapeutics?
No funding rounds, venture capital investments, or grants associated with C3J Therapeutics are documented in public databases or news reports. Without investment activity, the firm's financial backing and valuation remain unknown.
How does C3J Therapeutics compare to other companies targeting complement C3?
Competitors such as Apellis Pharmaceuticals (with pegcetacoplan, approved for geographic atrophy and PNH) and Amyndas Pharmaceuticals have well-documented pipelines and significant funding. C3J Therapeutics lacks comparable public resources, indicating a much earlier or less resourced stage of development.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: